Impath closes physician services business unit sale to Genzyme for $215 million in cash

Washington, May 4 - Impath Inc. closed the sale of its physician services business unit to Genzyme Corp. for $215 million in cash, according to Impath's advisor Crossroads LLC. Holly Felder Etlin, a Crossroads principal, is the company's chief restructuring officer.

New York-based Impath provides products and services that help doctors diagnose and treat cancer.

Impath filed for bankruptcy on Sept. 28, 2003. Its Chapter 11 case number is 03-16113.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.